NewsBenzingaRoth Capital avvia la copertura su Nautilus Biotechnology con rating Buy, annuncia un target di prezzo di 3,5 dollari Roth Capital avvia la copertura su Nautilus Biotechnology con rating Buy, annuncia un target di prezzo di 3,5 dollari Benzinga 2026.09.29 09:31 (GMT+0) Open on Benzinga Other news Gate Ventures: US stocks rebound and oil prices retreat, institutional access narrative in crypto market heats up Bank of New York Earnings Preview: What to Expect Oracle Bear Call Spread Could Net 20% in Under Two Months Slim Jim Maker Conagra Brands Braces for First Quarter Sales Drop to $2.59B as Analysts Lower Forecast for CAG Stock - TipRanks.com Micron Is in the ‘Best Cycle Anyone’ Has Ever Seen — MU Stock Is ‘in a Bubble,’ But Bulls Can Still Profit, Says Analyst Earnings Preview: What To Expect From Morgan Stanley's Report
Gate Ventures: US stocks rebound and oil prices retreat, institutional access narrative in crypto market heats up
Slim Jim Maker Conagra Brands Braces for First Quarter Sales Drop to $2.59B as Analysts Lower Forecast for CAG Stock - TipRanks.com
Micron Is in the ‘Best Cycle Anyone’ Has Ever Seen — MU Stock Is ‘in a Bubble,’ But Bulls Can Still Profit, Says Analyst
